Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 809 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Breaking down changes in NHS cancer waiting times in England August 17, 2023 How I Found a Meaningful Career After Cancer October 26, 2020 Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma April 29, 2021 FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell... July 11, 2025 Load more HOT NEWS Health inequalities: Why is it harder for some people to eat... EMA Recommends Granting a Marketing Authorisation for Ivosidenib Death Rates from Ovarian Cancer will Fall in the EU and... Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC...
